nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—HTR1D—meninx—melanoma	0.0428	0.268	CbGeAlD
Cabergoline—DRD5—eyelid—melanoma	0.0387	0.242	CbGeAlD
Cabergoline—Hemianopia—Temozolomide—melanoma	0.0236	0.0642	CcSEcCtD
Cabergoline—Leg edema—Temozolomide—melanoma	0.0101	0.0275	CcSEcCtD
Cabergoline—Fibrosis—Carmustine—melanoma	0.00987	0.0268	CcSEcCtD
Cabergoline—Vasospasm—Carmustine—melanoma	0.00825	0.0224	CcSEcCtD
Cabergoline—Periorbital oedema—Bleomycin—melanoma	0.00817	0.0222	CcSEcCtD
Cabergoline—Pulmonary fibrosis—Bleomycin—melanoma	0.00734	0.02	CcSEcCtD
Cabergoline—Pulmonary fibrosis—Carmustine—melanoma	0.00641	0.0174	CcSEcCtD
Cabergoline—Neoplasm malignant—Vemurafenib—melanoma	0.00624	0.017	CcSEcCtD
Cabergoline—Pulmonary fibrosis—Temozolomide—melanoma	0.0062	0.0168	CcSEcCtD
Cabergoline—Musculoskeletal pain—Vemurafenib—melanoma	0.0054	0.0147	CcSEcCtD
Cabergoline—HTR2A—hindlimb—melanoma	0.00505	0.0316	CbGeAlD
Cabergoline—HTR1B—blood vessel—melanoma	0.00501	0.0314	CbGeAlD
Cabergoline—HTR1D—blood vessel—melanoma	0.00485	0.0304	CbGeAlD
Cabergoline—Cerebration impaired—Temozolomide—melanoma	0.00463	0.0126	CcSEcCtD
Cabergoline—Pericardial effusion—Docetaxel—melanoma	0.00442	0.012	CcSEcCtD
Cabergoline—HTR2A—appendage—melanoma	0.00433	0.0271	CbGeAlD
Cabergoline—HTR7—endothelium—melanoma	0.00419	0.0262	CbGeAlD
Cabergoline—Hypokinesia—Carmustine—melanoma	0.00418	0.0113	CcSEcCtD
Cabergoline—Pulmonary fibrosis—Docetaxel—melanoma	0.00412	0.0112	CcSEcCtD
Cabergoline—HTR7—blood vessel—melanoma	0.00387	0.0242	CbGeAlD
Cabergoline—Influenza-like symptoms—Temozolomide—melanoma	0.00381	0.0104	CcSEcCtD
Cabergoline—Duodenal ulcer—Docetaxel—melanoma	0.00375	0.0102	CcSEcCtD
Cabergoline—Aggression—Bleomycin—melanoma	0.00368	0.00999	CcSEcCtD
Cabergoline—Disturbance in attention—Temozolomide—melanoma	0.00315	0.00855	CcSEcCtD
Cabergoline—Breast pain—Temozolomide—melanoma	0.00312	0.00849	CcSEcCtD
Cabergoline—Weight decreased—Vemurafenib—melanoma	0.00303	0.00822	CcSEcCtD
Cabergoline—Respiratory failure—Temozolomide—melanoma	0.00277	0.00754	CcSEcCtD
Cabergoline—HTR7—neck—melanoma	0.00277	0.0173	CbGeAlD
Cabergoline—Musculoskeletal pain—Temozolomide—melanoma	0.00276	0.00749	CcSEcCtD
Cabergoline—Influenza like illness—Temozolomide—melanoma	0.00265	0.00719	CcSEcCtD
Cabergoline—Oedema peripheral—Vemurafenib—melanoma	0.00264	0.00717	CcSEcCtD
Cabergoline—HTR2A—endothelium—melanoma	0.00261	0.0164	CbGeAlD
Cabergoline—DRD3—head—melanoma	0.00261	0.0163	CbGeAlD
Cabergoline—HTR1D—eye—melanoma	0.00258	0.0162	CbGeAlD
Cabergoline—Cardiac disorder—Vemurafenib—melanoma	0.00249	0.00675	CcSEcCtD
Cabergoline—Abnormal vision—Carmustine—melanoma	0.00246	0.00668	CcSEcCtD
Cabergoline—Mental disability—Carmustine—melanoma	0.00245	0.00665	CcSEcCtD
Cabergoline—DRD5—head—melanoma	0.00245	0.0153	CbGeAlD
Cabergoline—HTR2A—blood vessel—melanoma	0.00241	0.0151	CbGeAlD
Cabergoline—Abnormal vision—Temozolomide—melanoma	0.00238	0.00646	CcSEcCtD
Cabergoline—Pleural effusion—Docetaxel—melanoma	0.00237	0.00643	CcSEcCtD
Cabergoline—Alopecia—Vemurafenib—melanoma	0.00237	0.00643	CcSEcCtD
Cabergoline—Mental disability—Temozolomide—melanoma	0.00236	0.00642	CcSEcCtD
Cabergoline—Back pain—Vemurafenib—melanoma	0.00225	0.00613	CcSEcCtD
Cabergoline—Nasal congestion—Temozolomide—melanoma	0.00217	0.0059	CcSEcCtD
Cabergoline—Hot flush—Temozolomide—melanoma	0.00211	0.00574	CcSEcCtD
Cabergoline—Menopausal symptoms—Temozolomide—melanoma	0.0021	0.0057	CcSEcCtD
Cabergoline—HTR2B—skin of body—melanoma	0.00209	0.0131	CbGeAlD
Cabergoline—Liver function test abnormal—Dactinomycin—melanoma	0.00202	0.00549	CcSEcCtD
Cabergoline—ADRA1B—head—melanoma	0.002	0.0125	CbGeAlD
Cabergoline—Arthralgia—Vemurafenib—melanoma	0.00198	0.00539	CcSEcCtD
Cabergoline—Face oedema—Carmustine—melanoma	0.00198	0.00537	CcSEcCtD
Cabergoline—ADRA1D—head—melanoma	0.00196	0.0123	CbGeAlD
Cabergoline—DRD2—eye—melanoma	0.00195	0.0122	CbGeAlD
Cabergoline—DRD2—retina—melanoma	0.00193	0.0121	CbGeAlD
Cabergoline—Face oedema—Temozolomide—melanoma	0.00191	0.00519	CcSEcCtD
Cabergoline—Liver function test abnormal—Carmustine—melanoma	0.00189	0.00513	CcSEcCtD
Cabergoline—DRD1—head—melanoma	0.00187	0.0117	CbGeAlD
Cabergoline—Respiratory failure—Docetaxel—melanoma	0.00185	0.00501	CcSEcCtD
Cabergoline—Weight decreased—Bleomycin—melanoma	0.00183	0.00498	CcSEcCtD
Cabergoline—Pneumonia—Bleomycin—melanoma	0.00182	0.00494	CcSEcCtD
Cabergoline—Hypotension—Vemurafenib—melanoma	0.00178	0.00483	CcSEcCtD
Cabergoline—Influenza like illness—Docetaxel—melanoma	0.00176	0.00478	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00173	0.00471	CcSEcCtD
Cabergoline—HTR2A—neck—melanoma	0.00172	0.0108	CbGeAlD
Cabergoline—Pneumonia—Dactinomycin—melanoma	0.0017	0.00461	CcSEcCtD
Cabergoline—Sweating increased—Temozolomide—melanoma	0.00167	0.00452	CcSEcCtD
Cabergoline—Decreased appetite—Vemurafenib—melanoma	0.00165	0.00449	CcSEcCtD
Cabergoline—Bronchitis—Temozolomide—melanoma	0.00164	0.00447	CcSEcCtD
Cabergoline—Fatigue—Vemurafenib—melanoma	0.00164	0.00446	CcSEcCtD
Cabergoline—Constipation—Vemurafenib—melanoma	0.00163	0.00442	CcSEcCtD
Cabergoline—Lightheadedness—Docetaxel—melanoma	0.00162	0.0044	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Temozolomide—melanoma	0.00159	0.00432	CcSEcCtD
Cabergoline—Pneumonia—Carmustine—melanoma	0.00159	0.00431	CcSEcCtD
Cabergoline—Depression—Carmustine—melanoma	0.00157	0.00427	CcSEcCtD
Cabergoline—Weight increased—Temozolomide—melanoma	0.00156	0.00423	CcSEcCtD
Cabergoline—Weight decreased—Temozolomide—melanoma	0.00155	0.0042	CcSEcCtD
Cabergoline—Urinary tract infection—Carmustine—melanoma	0.00153	0.00417	CcSEcCtD
Cabergoline—Pneumonia—Temozolomide—melanoma	0.00153	0.00417	CcSEcCtD
Cabergoline—Depression—Temozolomide—melanoma	0.00152	0.00413	CcSEcCtD
Cabergoline—HTR1B—head—melanoma	0.00151	0.00948	CbGeAlD
Cabergoline—ADRA2C—mammalian vulva—melanoma	0.0015	0.00939	CbGeAlD
Cabergoline—Urinary tract infection—Temozolomide—melanoma	0.00148	0.00403	CcSEcCtD
Cabergoline—HTR1D—head—melanoma	0.00147	0.00917	CbGeAlD
Cabergoline—HTR2C—head—melanoma	0.00145	0.00908	CbGeAlD
Cabergoline—Alopecia—Bleomycin—melanoma	0.00143	0.00389	CcSEcCtD
Cabergoline—ADRB1—head—melanoma	0.00142	0.00891	CbGeAlD
Cabergoline—Hallucination—Carmustine—melanoma	0.00141	0.00383	CcSEcCtD
Cabergoline—Hot flush—Docetaxel—melanoma	0.00141	0.00382	CcSEcCtD
Cabergoline—Hypersensitivity—Vemurafenib—melanoma	0.0014	0.00381	CcSEcCtD
Cabergoline—Oedema peripheral—Carmustine—melanoma	0.00139	0.00379	CcSEcCtD
Cabergoline—Menopausal symptoms—Docetaxel—melanoma	0.00139	0.00379	CcSEcCtD
Cabergoline—Asthenia—Vemurafenib—melanoma	0.00136	0.00371	CcSEcCtD
Cabergoline—Visual impairment—Carmustine—melanoma	0.00136	0.00371	CcSEcCtD
Cabergoline—HTR2B—head—melanoma	0.00136	0.00853	CbGeAlD
Cabergoline—Hallucination—Temozolomide—melanoma	0.00136	0.0037	CcSEcCtD
Cabergoline—Oedema peripheral—Temozolomide—melanoma	0.00135	0.00366	CcSEcCtD
Cabergoline—Cardiac failure—Docetaxel—melanoma	0.00135	0.00366	CcSEcCtD
Cabergoline—Pruritus—Vemurafenib—melanoma	0.00135	0.00366	CcSEcCtD
Cabergoline—Alopecia—Dactinomycin—melanoma	0.00134	0.00363	CcSEcCtD
Cabergoline—Visual impairment—Temozolomide—melanoma	0.00132	0.00358	CcSEcCtD
Cabergoline—Ill-defined disorder—Bleomycin—melanoma	0.00131	0.00356	CcSEcCtD
Cabergoline—Diarrhoea—Vemurafenib—melanoma	0.0013	0.00354	CcSEcCtD
Cabergoline—HTR2A—eye—melanoma	0.00128	0.00803	CbGeAlD
Cabergoline—Malaise—Bleomycin—melanoma	0.00127	0.00346	CcSEcCtD
Cabergoline—HTR2A—retina—melanoma	0.00127	0.00796	CbGeAlD
Cabergoline—Cardiac disorder—Temozolomide—melanoma	0.00127	0.00345	CcSEcCtD
Cabergoline—Arrhythmia—Carmustine—melanoma	0.00127	0.00344	CcSEcCtD
Cabergoline—Dizziness—Vemurafenib—melanoma	0.00126	0.00342	CcSEcCtD
Cabergoline—Alopecia—Carmustine—melanoma	0.00125	0.0034	CcSEcCtD
Cabergoline—Ill-defined disorder—Dactinomycin—melanoma	0.00122	0.00332	CcSEcCtD
Cabergoline—HTR1A—head—melanoma	0.00122	0.00765	CbGeAlD
Cabergoline—Liver function test abnormal—Docetaxel—melanoma	0.00121	0.0033	CcSEcCtD
Cabergoline—Vomiting—Vemurafenib—melanoma	0.00121	0.00329	CcSEcCtD
Cabergoline—Alopecia—Temozolomide—melanoma	0.00121	0.00329	CcSEcCtD
Cabergoline—Abdominal pain upper—Docetaxel—melanoma	0.0012	0.00326	CcSEcCtD
Cabergoline—Orthostatic hypotension—Docetaxel—melanoma	0.0012	0.00326	CcSEcCtD
Cabergoline—Rash—Vemurafenib—melanoma	0.0012	0.00326	CcSEcCtD
Cabergoline—Dermatitis—Vemurafenib—melanoma	0.0012	0.00326	CcSEcCtD
Cabergoline—ADRA2A—mammalian vulva—melanoma	0.0012	0.00749	CbGeAlD
Cabergoline—Back pain—Carmustine—melanoma	0.00119	0.00324	CcSEcCtD
Cabergoline—Headache—Vemurafenib—melanoma	0.00119	0.00324	CcSEcCtD
Cabergoline—Discomfort—Bleomycin—melanoma	0.00119	0.00323	CcSEcCtD
Cabergoline—Malaise—Dactinomycin—melanoma	0.00119	0.00323	CcSEcCtD
Cabergoline—HTR7—head—melanoma	0.00117	0.00731	CbGeAlD
Cabergoline—Confusional state—Bleomycin—melanoma	0.00116	0.00316	CcSEcCtD
Cabergoline—Oedema—Bleomycin—melanoma	0.00115	0.00313	CcSEcCtD
Cabergoline—Back pain—Temozolomide—melanoma	0.00115	0.00313	CcSEcCtD
Cabergoline—Nausea—Vemurafenib—melanoma	0.00113	0.00307	CcSEcCtD
Cabergoline—ADRA1A—head—melanoma	0.00113	0.00705	CbGeAlD
Cabergoline—Discomfort—Dactinomycin—melanoma	0.00111	0.00301	CcSEcCtD
Cabergoline—Ill-defined disorder—Temozolomide—melanoma	0.00111	0.003	CcSEcCtD
Cabergoline—DRD2—head—melanoma	0.0011	0.00691	CbGeAlD
Cabergoline—Anorexia—Bleomycin—melanoma	0.0011	0.00298	CcSEcCtD
Cabergoline—Hypotension—Bleomycin—melanoma	0.00108	0.00293	CcSEcCtD
Cabergoline—Oedema—Dactinomycin—melanoma	0.00107	0.00292	CcSEcCtD
Cabergoline—Malaise—Temozolomide—melanoma	0.00107	0.00292	CcSEcCtD
Cabergoline—ADRA2C—head—melanoma	0.00107	0.00672	CbGeAlD
Cabergoline—Vertigo—Temozolomide—melanoma	0.00107	0.00291	CcSEcCtD
Cabergoline—Hypertension—Carmustine—melanoma	0.00106	0.00289	CcSEcCtD
Cabergoline—Palpitations—Temozolomide—melanoma	0.00105	0.00286	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Bleomycin—melanoma	0.00105	0.00285	CcSEcCtD
Cabergoline—Anxiety—Carmustine—melanoma	0.00105	0.00284	CcSEcCtD
Cabergoline—Paraesthesia—Bleomycin—melanoma	0.00103	0.00281	CcSEcCtD
Cabergoline—Weight increased—Docetaxel—melanoma	0.00103	0.00281	CcSEcCtD
Cabergoline—Weight decreased—Docetaxel—melanoma	0.00103	0.00279	CcSEcCtD
Cabergoline—Hypertension—Temozolomide—melanoma	0.00103	0.00279	CcSEcCtD
Cabergoline—Dyspnoea—Bleomycin—melanoma	0.00103	0.00279	CcSEcCtD
Cabergoline—Anorexia—Dactinomycin—melanoma	0.00102	0.00278	CcSEcCtD
Cabergoline—Pneumonia—Docetaxel—melanoma	0.00102	0.00277	CcSEcCtD
Cabergoline—Confusional state—Carmustine—melanoma	0.00101	0.00276	CcSEcCtD
Cabergoline—Arthralgia—Temozolomide—melanoma	0.00101	0.00276	CcSEcCtD
Cabergoline—Anxiety—Temozolomide—melanoma	0.00101	0.00275	CcSEcCtD
Cabergoline—Oedema—Carmustine—melanoma	0.00101	0.00273	CcSEcCtD
Cabergoline—Discomfort—Temozolomide—melanoma	0.001	0.00272	CcSEcCtD
Cabergoline—Decreased appetite—Bleomycin—melanoma	0.001	0.00272	CcSEcCtD
Cabergoline—Dry mouth—Temozolomide—melanoma	0.000992	0.00269	CcSEcCtD
Cabergoline—Pain—Bleomycin—melanoma	0.000986	0.00268	CcSEcCtD
Cabergoline—Confusional state—Temozolomide—melanoma	0.00098	0.00266	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000979	0.00266	CcSEcCtD
Cabergoline—Oedema—Temozolomide—melanoma	0.000972	0.00264	CcSEcCtD
Cabergoline—Anorexia—Carmustine—melanoma	0.000959	0.00261	CcSEcCtD
Cabergoline—Epistaxis—Docetaxel—melanoma	0.000956	0.0026	CcSEcCtD
Cabergoline—HTR2B—lymph node—melanoma	0.000955	0.00598	CbGeAlD
Cabergoline—Feeling abnormal—Bleomycin—melanoma	0.00095	0.00258	CcSEcCtD
Cabergoline—Hypotension—Carmustine—melanoma	0.00094	0.00255	CcSEcCtD
Cabergoline—Hyperhidrosis—Temozolomide—melanoma	0.00094	0.00255	CcSEcCtD
Cabergoline—Decreased appetite—Dactinomycin—melanoma	0.000934	0.00254	CcSEcCtD
Cabergoline—Fatigue—Dactinomycin—melanoma	0.000927	0.00252	CcSEcCtD
Cabergoline—Anorexia—Temozolomide—melanoma	0.000927	0.00252	CcSEcCtD
Cabergoline—Pain—Dactinomycin—melanoma	0.000919	0.0025	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Carmustine—melanoma	0.000917	0.00249	CcSEcCtD
Cabergoline—Rhinitis—Docetaxel—melanoma	0.000912	0.00248	CcSEcCtD
Cabergoline—Insomnia—Carmustine—melanoma	0.00091	0.00247	CcSEcCtD
Cabergoline—Paraesthesia—Carmustine—melanoma	0.000903	0.00245	CcSEcCtD
Cabergoline—Dyspnoea—Carmustine—melanoma	0.000897	0.00244	CcSEcCtD
Cabergoline—Oedema peripheral—Docetaxel—melanoma	0.000896	0.00244	CcSEcCtD
Cabergoline—Somnolence—Carmustine—melanoma	0.000894	0.00243	CcSEcCtD
Cabergoline—Feeling abnormal—Dactinomycin—melanoma	0.000886	0.00241	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Temozolomide—melanoma	0.000886	0.00241	CcSEcCtD
Cabergoline—Insomnia—Temozolomide—melanoma	0.000879	0.00239	CcSEcCtD
Cabergoline—Gastrointestinal pain—Dactinomycin—melanoma	0.000879	0.00239	CcSEcCtD
Cabergoline—Visual impairment—Docetaxel—melanoma	0.000877	0.00238	CcSEcCtD
Cabergoline—Decreased appetite—Carmustine—melanoma	0.000875	0.00238	CcSEcCtD
Cabergoline—Paraesthesia—Temozolomide—melanoma	0.000873	0.00237	CcSEcCtD
Cabergoline—Dyspnoea—Temozolomide—melanoma	0.000867	0.00235	CcSEcCtD
Cabergoline—Somnolence—Temozolomide—melanoma	0.000864	0.00235	CcSEcCtD
Cabergoline—Constipation—Carmustine—melanoma	0.00086	0.00234	CcSEcCtD
Cabergoline—Pain—Carmustine—melanoma	0.00086	0.00234	CcSEcCtD
Cabergoline—ADRA2A—head—melanoma	0.000856	0.00536	CbGeAlD
Cabergoline—Dyspepsia—Temozolomide—melanoma	0.000856	0.00233	CcSEcCtD
Cabergoline—Abdominal pain—Dactinomycin—melanoma	0.00085	0.00231	CcSEcCtD
Cabergoline—Hypersensitivity—Bleomycin—melanoma	0.000849	0.00231	CcSEcCtD
Cabergoline—Decreased appetite—Temozolomide—melanoma	0.000845	0.0023	CcSEcCtD
Cabergoline—Cardiac disorder—Docetaxel—melanoma	0.000845	0.00229	CcSEcCtD
Cabergoline—Fatigue—Temozolomide—melanoma	0.000838	0.00228	CcSEcCtD
Cabergoline—Pain—Temozolomide—melanoma	0.000831	0.00226	CcSEcCtD
Cabergoline—Constipation—Temozolomide—melanoma	0.000831	0.00226	CcSEcCtD
Cabergoline—Feeling abnormal—Carmustine—melanoma	0.000829	0.00225	CcSEcCtD
Cabergoline—Asthenia—Bleomycin—melanoma	0.000827	0.00225	CcSEcCtD
Cabergoline—Gastrointestinal pain—Carmustine—melanoma	0.000823	0.00223	CcSEcCtD
Cabergoline—Pruritus—Bleomycin—melanoma	0.000815	0.00222	CcSEcCtD
Cabergoline—Arrhythmia—Docetaxel—melanoma	0.000813	0.00221	CcSEcCtD
Cabergoline—Alopecia—Docetaxel—melanoma	0.000804	0.00218	CcSEcCtD
Cabergoline—Feeling abnormal—Temozolomide—melanoma	0.000801	0.00218	CcSEcCtD
Cabergoline—Abdominal pain—Carmustine—melanoma	0.000795	0.00216	CcSEcCtD
Cabergoline—Gastrointestinal pain—Temozolomide—melanoma	0.000795	0.00216	CcSEcCtD
Cabergoline—Hypersensitivity—Dactinomycin—melanoma	0.000792	0.00215	CcSEcCtD
Cabergoline—Asthenia—Dactinomycin—melanoma	0.000771	0.0021	CcSEcCtD
Cabergoline—Abdominal pain—Temozolomide—melanoma	0.000769	0.00209	CcSEcCtD
Cabergoline—Back pain—Docetaxel—melanoma	0.000766	0.00208	CcSEcCtD
Cabergoline—Muscle spasms—Docetaxel—melanoma	0.000762	0.00207	CcSEcCtD
Cabergoline—ADRA2C—lymph node—melanoma	0.000752	0.0047	CbGeAlD
Cabergoline—Hypersensitivity—Carmustine—melanoma	0.000741	0.00201	CcSEcCtD
Cabergoline—Diarrhoea—Dactinomycin—melanoma	0.000735	0.002	CcSEcCtD
Cabergoline—Vomiting—Bleomycin—melanoma	0.000733	0.00199	CcSEcCtD
Cabergoline—HTR2A—head—melanoma	0.000728	0.00456	CbGeAlD
Cabergoline—Rash—Bleomycin—melanoma	0.000727	0.00197	CcSEcCtD
Cabergoline—Dermatitis—Bleomycin—melanoma	0.000726	0.00197	CcSEcCtD
Cabergoline—Asthenia—Carmustine—melanoma	0.000722	0.00196	CcSEcCtD
Cabergoline—Hypersensitivity—Temozolomide—melanoma	0.000716	0.00195	CcSEcCtD
Cabergoline—Syncope—Docetaxel—melanoma	0.00071	0.00193	CcSEcCtD
Cabergoline—Palpitations—Docetaxel—melanoma	0.0007	0.0019	CcSEcCtD
Cabergoline—Asthenia—Temozolomide—melanoma	0.000698	0.0019	CcSEcCtD
Cabergoline—Loss of consciousness—Docetaxel—melanoma	0.000696	0.00189	CcSEcCtD
Cabergoline—Diarrhoea—Carmustine—melanoma	0.000688	0.00187	CcSEcCtD
Cabergoline—Pruritus—Temozolomide—melanoma	0.000688	0.00187	CcSEcCtD
Cabergoline—Nausea—Bleomycin—melanoma	0.000685	0.00186	CcSEcCtD
Cabergoline—Hypertension—Docetaxel—melanoma	0.000684	0.00186	CcSEcCtD
Cabergoline—Vomiting—Dactinomycin—melanoma	0.000683	0.00186	CcSEcCtD
Cabergoline—Rash—Dactinomycin—melanoma	0.000678	0.00184	CcSEcCtD
Cabergoline—Arthralgia—Docetaxel—melanoma	0.000674	0.00183	CcSEcCtD
Cabergoline—Dizziness—Carmustine—melanoma	0.000665	0.00181	CcSEcCtD
Cabergoline—Diarrhoea—Temozolomide—melanoma	0.000665	0.00181	CcSEcCtD
Cabergoline—Dry mouth—Docetaxel—melanoma	0.00066	0.00179	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—melanoma	0.000652	0.00177	CcSEcCtD
Cabergoline—Oedema—Docetaxel—melanoma	0.000647	0.00176	CcSEcCtD
Cabergoline—Dizziness—Temozolomide—melanoma	0.000643	0.00175	CcSEcCtD
Cabergoline—Vomiting—Carmustine—melanoma	0.00064	0.00174	CcSEcCtD
Cabergoline—Nausea—Dactinomycin—melanoma	0.000638	0.00173	CcSEcCtD
Cabergoline—Shock—Docetaxel—melanoma	0.000636	0.00173	CcSEcCtD
Cabergoline—Rash—Carmustine—melanoma	0.000634	0.00172	CcSEcCtD
Cabergoline—Dermatitis—Carmustine—melanoma	0.000634	0.00172	CcSEcCtD
Cabergoline—Headache—Carmustine—melanoma	0.00063	0.00171	CcSEcCtD
Cabergoline—Vomiting—Temozolomide—melanoma	0.000618	0.00168	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—melanoma	0.000616	0.00167	CcSEcCtD
Cabergoline—Rash—Temozolomide—melanoma	0.000613	0.00167	CcSEcCtD
Cabergoline—Dermatitis—Temozolomide—melanoma	0.000612	0.00166	CcSEcCtD
Cabergoline—Headache—Temozolomide—melanoma	0.000609	0.00165	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—melanoma	0.000604	0.00164	CcSEcCtD
Cabergoline—ADRA2A—lymph node—melanoma	0.0006	0.00375	CbGeAlD
Cabergoline—Nausea—Carmustine—melanoma	0.000598	0.00162	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—melanoma	0.000589	0.0016	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—melanoma	0.000585	0.00159	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—melanoma	0.000581	0.00158	CcSEcCtD
Cabergoline—Nausea—Temozolomide—melanoma	0.000577	0.00157	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—melanoma	0.000576	0.00157	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—melanoma	0.000575	0.00156	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—melanoma	0.000569	0.00155	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—melanoma	0.000562	0.00153	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—melanoma	0.000557	0.00151	CcSEcCtD
Cabergoline—Constipation—Docetaxel—melanoma	0.000553	0.0015	CcSEcCtD
Cabergoline—Pain—Docetaxel—melanoma	0.000553	0.0015	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—melanoma	0.000533	0.00145	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—melanoma	0.000529	0.00144	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—melanoma	0.000511	0.00139	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—melanoma	0.000476	0.00129	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—melanoma	0.000464	0.00126	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—melanoma	0.000457	0.00124	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—melanoma	0.000442	0.0012	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—melanoma	0.000428	0.00116	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—melanoma	0.000411	0.00112	CcSEcCtD
Cabergoline—Rash—Docetaxel—melanoma	0.000408	0.00111	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—melanoma	0.000407	0.00111	CcSEcCtD
Cabergoline—Headache—Docetaxel—melanoma	0.000405	0.0011	CcSEcCtD
Cabergoline—Nausea—Docetaxel—melanoma	0.000384	0.00104	CcSEcCtD
Cabergoline—DRD2—Signaling Pathways—IL2—melanoma	9.73e-06	2.06e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MAPK1—melanoma	9.73e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MAPK1—melanoma	9.73e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NRAS—melanoma	9.72e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—melanoma	9.72e-06	2.06e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—melanoma	9.72e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—melanoma	9.69e-06	2.05e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—melanoma	9.68e-06	2.05e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—melanoma	9.68e-06	2.05e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—melanoma	9.66e-06	2.05e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—melanoma	9.66e-06	2.05e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—melanoma	9.64e-06	2.04e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—melanoma	9.63e-06	2.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—ERBB2—melanoma	9.61e-06	2.04e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—melanoma	9.6e-06	2.03e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—melanoma	9.59e-06	2.03e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1B—melanoma	9.58e-06	2.03e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—melanoma	9.57e-06	2.03e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—melanoma	9.54e-06	2.02e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—melanoma	9.54e-06	2.02e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—melanoma	9.53e-06	2.02e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—melanoma	9.51e-06	2.02e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—melanoma	9.5e-06	2.01e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—melanoma	9.48e-06	2.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—melanoma	9.48e-06	2.01e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—melanoma	9.48e-06	2.01e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—melanoma	9.42e-06	1.99e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CTNNB1—melanoma	9.39e-06	1.99e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—melanoma	9.39e-06	1.99e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—melanoma	9.37e-06	1.99e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—melanoma	9.37e-06	1.98e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—melanoma	9.34e-06	1.98e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—melanoma	9.33e-06	1.98e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—melanoma	9.33e-06	1.98e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—melanoma	9.32e-06	1.98e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—melanoma	9.31e-06	1.97e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—melanoma	9.31e-06	1.97e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—melanoma	9.3e-06	1.97e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—melanoma	9.28e-06	1.96e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NRAS—melanoma	9.25e-06	1.96e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CTNNB1—melanoma	9.24e-06	1.96e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—melanoma	9.23e-06	1.95e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—melanoma	9.21e-06	1.95e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—melanoma	9.19e-06	1.95e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—melanoma	9.19e-06	1.95e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—melanoma	9.19e-06	1.95e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—melanoma	9.18e-06	1.95e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CDKN1A—melanoma	9.18e-06	1.94e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—melanoma	9.15e-06	1.94e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—melanoma	9.14e-06	1.94e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—melanoma	9.12e-06	1.93e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—melanoma	9.11e-06	1.93e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—melanoma	9.11e-06	1.93e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—melanoma	9.11e-06	1.93e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NFKB1—melanoma	9.11e-06	1.93e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—melanoma	9.07e-06	1.92e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—melanoma	9.06e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—melanoma	9.06e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—melanoma	9.05e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CTNNB1—melanoma	9.05e-06	1.92e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1A—melanoma	9.03e-06	1.91e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—melanoma	9.02e-06	1.91e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—melanoma	9.01e-06	1.91e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—melanoma	9e-06	1.91e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—melanoma	8.98e-06	1.9e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—melanoma	8.97e-06	1.9e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NFKB1—melanoma	8.96e-06	1.9e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—melanoma	8.93e-06	1.89e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—melanoma	8.93e-06	1.89e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—melanoma	8.91e-06	1.89e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1B—melanoma	8.9e-06	1.89e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—melanoma	8.88e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—melanoma	8.87e-06	1.88e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—melanoma	8.86e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK1—melanoma	8.86e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—melanoma	8.86e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—melanoma	8.86e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—melanoma	8.86e-06	1.88e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1A—melanoma	8.84e-06	1.87e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—melanoma	8.82e-06	1.87e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—melanoma	8.8e-06	1.86e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—melanoma	8.79e-06	1.86e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—melanoma	8.79e-06	1.86e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—melanoma	8.79e-06	1.86e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK1—melanoma	8.78e-06	1.86e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—melanoma	8.78e-06	1.86e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NFKB1—melanoma	8.78e-06	1.86e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—melanoma	8.77e-06	1.86e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCB1—melanoma	8.75e-06	1.85e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—melanoma	8.73e-06	1.85e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—melanoma	8.72e-06	1.85e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—melanoma	8.71e-06	1.84e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK1—melanoma	8.67e-06	1.84e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—melanoma	8.67e-06	1.84e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—melanoma	8.67e-06	1.84e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—melanoma	8.66e-06	1.84e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—melanoma	8.62e-06	1.83e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—melanoma	8.62e-06	1.83e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—melanoma	8.6e-06	1.82e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—melanoma	8.55e-06	1.81e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—melanoma	8.55e-06	1.81e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—melanoma	8.51e-06	1.8e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—melanoma	8.49e-06	1.8e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—melanoma	8.48e-06	1.8e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK1—melanoma	8.48e-06	1.8e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—melanoma	8.47e-06	1.8e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—melanoma	8.44e-06	1.79e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—melanoma	8.44e-06	1.79e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK1—melanoma	8.43e-06	1.79e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—melanoma	8.43e-06	1.79e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—melanoma	8.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CTNNB1—melanoma	8.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—melanoma	8.39e-06	1.78e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—melanoma	8.38e-06	1.78e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—melanoma	8.37e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—melanoma	8.29e-06	1.76e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—melanoma	8.27e-06	1.75e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—melanoma	8.27e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—melanoma	8.25e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—melanoma	8.24e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1A—melanoma	8.21e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK1—melanoma	8.2e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—melanoma	8.2e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—melanoma	8.19e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—melanoma	8.19e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—melanoma	8.19e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—melanoma	8.17e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—melanoma	8.16e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—melanoma	8.16e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NFKB1—melanoma	8.16e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—melanoma	8.14e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—melanoma	8.11e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK1—melanoma	8.07e-06	1.71e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—melanoma	8.07e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—melanoma	8.06e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—melanoma	8.06e-06	1.71e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PRKCA—melanoma	8.05e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—melanoma	8.04e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—melanoma	8.03e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—melanoma	8.01e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—melanoma	7.99e-06	1.69e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ERCC2—melanoma	7.98e-06	1.69e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—melanoma	7.97e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—melanoma	7.96e-06	1.69e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—melanoma	7.91e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—melanoma	7.89e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—melanoma	7.89e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—melanoma	7.87e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—melanoma	7.82e-06	1.66e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—melanoma	7.81e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—melanoma	7.81e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—melanoma	7.76e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—melanoma	7.75e-06	1.64e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—melanoma	7.7e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—melanoma	7.69e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—melanoma	7.62e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—melanoma	7.62e-06	1.61e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—melanoma	7.61e-06	1.61e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—melanoma	7.57e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—melanoma	7.54e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—melanoma	7.52e-06	1.59e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—melanoma	7.49e-06	1.59e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—melanoma	7.47e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—melanoma	7.47e-06	1.58e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK1—melanoma	7.44e-06	1.58e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—melanoma	7.44e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—melanoma	7.44e-06	1.58e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—melanoma	7.41e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—melanoma	7.4e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—melanoma	7.37e-06	1.56e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—melanoma	7.36e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—melanoma	7.33e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—melanoma	7.33e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK1—melanoma	7.32e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—melanoma	7.32e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—melanoma	7.32e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—melanoma	7.31e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—melanoma	7.28e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK1—melanoma	7.17e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—melanoma	7.17e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—melanoma	7.12e-06	1.51e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—melanoma	7.12e-06	1.51e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—melanoma	7.11e-06	1.51e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—melanoma	7.08e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—melanoma	7.05e-06	1.49e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—melanoma	7.03e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—melanoma	7e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—melanoma	7e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—melanoma	6.99e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—melanoma	6.96e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—melanoma	6.95e-06	1.47e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—melanoma	6.92e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—melanoma	6.91e-06	1.46e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—melanoma	6.89e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—melanoma	6.89e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—melanoma	6.89e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—melanoma	6.81e-06	1.44e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—melanoma	6.81e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—melanoma	6.81e-06	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—melanoma	6.78e-06	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—melanoma	6.77e-06	1.43e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—melanoma	6.77e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—melanoma	6.75e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK1—melanoma	6.66e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—melanoma	6.66e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—melanoma	6.66e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—melanoma	6.58e-06	1.39e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—melanoma	6.51e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—melanoma	6.48e-06	1.37e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—melanoma	6.48e-06	1.37e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—melanoma	6.46e-06	1.37e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—melanoma	6.35e-06	1.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—melanoma	6.31e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—melanoma	6.3e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—melanoma	6.29e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—melanoma	6.28e-06	1.33e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—melanoma	6.25e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—melanoma	6.22e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—melanoma	6.22e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—melanoma	6.2e-06	1.31e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—melanoma	6.15e-06	1.3e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—melanoma	6.15e-06	1.3e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—melanoma	6.09e-06	1.29e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—melanoma	6.02e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—melanoma	6.01e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—melanoma	5.98e-06	1.27e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—melanoma	5.97e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—melanoma	5.88e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—melanoma	5.81e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—melanoma	5.78e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—melanoma	5.76e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—melanoma	5.72e-06	1.21e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—melanoma	5.72e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—melanoma	5.65e-06	1.2e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—melanoma	5.63e-06	1.19e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—melanoma	5.59e-06	1.18e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—melanoma	5.54e-06	1.17e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—melanoma	5.51e-06	1.17e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—melanoma	5.47e-06	1.16e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—melanoma	5.35e-06	1.13e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—melanoma	5.28e-06	1.12e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—melanoma	5.19e-06	1.1e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—melanoma	5.12e-06	1.08e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—melanoma	5.08e-06	1.08e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—melanoma	4.83e-06	1.02e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—melanoma	4.79e-06	1.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—melanoma	4.72e-06	1e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—melanoma	4.18e-06	8.84e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—melanoma	2.95e-06	6.24e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—melanoma	2.41e-06	5.1e-06	CbGpPWpGaD
